Tricuspid regurgitation (TR) is a cardiac disorder occurring when the tricuspid valve leaks during systole. This causes blood backflow and results in decreased cardiac output. TR is the most common valvular heart disease affecting 65%-85% of the global population in its mild form. However, mild TR can progress to severe TR, leading to heart failure or death if left untreated. Today, the only option for treatment is valve repair or replacement through open-heart surgery, which represents with high mortality rates, risks, and costs. Over 3M patients suffer from TR in Europe. For the majority, their condition is too severe for surgery. Therefore, there is no effective treatment.

Innoventric has developed the Trillium™ – a transcatheter tricuspid valve replacement solution. The whole procedure is minimally invasive and can be completed in 30mins. Within the EIC project, Innoventric will finalize the clinical validation of its device, ensuring safe and timely intervention for TR patients.